Some of the factors that could cause actual results to differ include: our ability to continue to monetize the licensing of our technology and products; our ability to raise capital; our ability to achieve profitability; our ability to manage our growth effectively; our ability to obtain FDA clearance for our Modified Risk Cigarettes; our ability t
Aug. 03 DOVER Stakeholders and policy makers in healthcare delivery gathered Monday for a community discussion with Executive Councilor Colin Van Ostern at Wentworth-Douglass Hospital in Dover. Van Ostern set up the gathering to focus on Medicaid expansion, efforts to combat the heroin epidemic, family planning services, and upcoming steps in t
Examples of these statements include, but are not limited to, statements regarding: the process and timing of anticipated future development of AcelRx's product candidates, including Zalviso and ARX-04, including the upcoming General Advice meeting with the U.S. Food and Drug Administration, or FDA, for Zalviso scheduled in early September 2015; Ac
A decision by the European Commission on the approval of Zalviso is anticipated in late September or early October.? AcelRx has been granted a General Advice meeting with the U.S. Food and Drug Administration in early September to discuss the FDA's request for a clinical trial and the company's planned response to the Complete Response Letter iss
We offer a broad range of traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities, Medicaid health care management services, Medicare Advantage and Medicare supplement plans, workers'...
Antares Pharma, Inc. today announced that the first patients have been enrolled in a double-blind, multiple-dose, 26- week safety and pharmacokinetic study of QuickShot Testosterone administered subcutaneously once each week to adult males with hypogonadism. The Company has been working closely with the Food and Drug Administration and we bel
The new collaboration builds on a broad existing relationship between the two companies and supports AstraZeneca's strategic approach in these therapeutic areas using novel RNA-targeted treatments. AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals plus development and regulatory milestones for each program that...
At the coalition event, Christine Ruhl, RN, BSN, MBA, CCRN, Director, Critical Care Services at Western Maryland Health System presented their process for achieving and sustaining 100% hospital wide drug library compliance within 6 months by utilizing B.Braun' s DoseTrac Real-time view, reporting/analytics and unit based audits. Cheryl Grogg, RN
Release date- 03082015- BRIDGEWATER, NJ- Bausch+ Lomb, a leading global eye health company, announced today its VICTUS Femtosecond Laser Platform has received 510 clearance from the U.S. Food and Drug Administration for an enhanced patient interface kit. The interface features a smaller diameter suction clip, which has been modified to allow for ea
Bayer HealthCare has received approval from the US Food and Drug Administration for Finacea Foam, 15% for the topical treatment of the inflammatory papules and pustules of mild to moderate rosacea. The FDA approval is based on results from two pivotal clinical trials evaluating the efficacy and safety of Finacea Foam compared to the foam vehicle in
BC Technical, Inc., a provider of medical imaging solutions, has acquired Ohio Valley Medical Systems, LLC, a provider of a MRI service. The acquisition of Ohio Valley Medical Systems helps solidify BC Technical s position as the nationwide, independent service, systems and parts provider for CT, MR, NM, PET and PET/CT, and the only viable alter
Reading, UK- Prolifics, a global technology solutions provider, today announced that BMI Healthcare, the UK's largest independent hospital group, is working with IBM and Prolifics to improve its technology infrastructure, assisting its clinicians in delivering quality patient outcomes. BMI Healthcare is deploying IBM Integration Bus to streamline a
-Cambia Health Solutions has promoted Scott Powers to President of Government Programs, with accountability for overall performance of the company s Medicare and Federal Employee Programs lines of business. Scott is a proven leader focused on transforming health care, said Jared Short, president of Regence Health Insurance Services. He
By a News Reporter-Staff News Editor at China Weekly News Cardiome Pharma Corp. announced that its Chinese development and commercialization partner, Eddingpharm, plans to initiate a Phase 1 study for BRINAVESS? to support regulatory approval in China. "We are pleased that Eddingpharm is taking the first steps necessary to gain approval of BRI
Cassiopea announces that the FDA has agreed to the Special Protocol for the Winlevi phase III trial. Lainate, August 4, 2015; Cassiopea SpA, a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products addressed to the topical treatment of acne, androgenic...
Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Catabasis will present a company overview at the Wedbush PacGrow Healthcare Conference. The Wedbush PacGrow Healthcare Conference will be held August 11- 12, 2015, in New York, NY at Le Parker Meridien
CDPHP has announced the results of a study that show the health plan's Enhanced Primary Care initiative produced an impressive $20.7 million in savings in 2014, all while improving the quality of care for hundreds of thousands of patients. In 2008, after noting a decline in the number of local medical students who were choosing to become primary
Celator Pharmaceuticals, Inc., a biopharmaceutical company that is transforming the science of combination therapy and developing products to improve patient outcomes in cancer, today announced that it will host a conference call and live audio webcast on Tuesday, August 11, 2015 at 4:30 p.m. ET to report second quarter 2015 financial results.
Investor advocates worry about privacy issues or brokers overstepping their authority, for example, or health care facilities' conflicts of interest if they appeal to a court for guardianship so they can get Medicaid reimbursements. "We still have way too many older folks believing that Nigerian prince is their friend," said Ron Long, head of regu
Ciclofilin Pharmaceuticals Inc., a privately held biotech, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Number 13/ 994,707 entitled, "Cyclosporine Analogue Molecules Modified at Amino Acid 1 and 3." This Intellectual Property expands the Company's portfolio of...
-Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510 submission for Dermadexin? to the U.S. Food& Drug Administration. "The acceptance of our Dermadexin? submission marks Cipher's first regulatory filing with the FDA since Absorica in 2011," said Shawn Patrick O'Brien, President and
-Cipher Pharmaceuticals Inc. today announced that it has received an Acceptance Review Notification for its 510 submission for Dermadexin? to the U.S. Food& Drug Administration. "The acceptance of our Dermadexin? submission marks Cipher's first regulatory filing with the FDA since Absorica in 2011," said Shawn Patrick O' Brien, President an
Release date- 03082015- DUBLIN-Medtronic plc announced today that the U.S. Centers for Medicare and Medicaid Services has granted a New Technology Add-on Payment for the company's IN.PACT Admiral drug-coated balloon under the Medicare hospital inpatient prospective payment system. 'Medtronic has been leading the efforts with CMS to enhance access t
Additionally, the study demonstrated that the Medicare covered Decipher test is an independent predictor of metastasis in African American men. The study, titled " Novel Biomarker Signature That May Predict Aggressive Disease in African American Men with Prostate Cancer," was published this month online ahead of print in the latest issue of the Jou
We urge you to carefully review and consider the various disclosures made by us in this Report and in our other reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10- K, which discusses our business and related risks in greater detail, as well as subsequent reports we may file from time to time on Forms 1